Several studies have demonstrated that activins can induce MEK-ERK1/2 signaling, and our finding that MEK inhibition blocks activin A-induced endometrial cancer cell migration is consistent with previous studies in mesothelioma and mesenchymal stem cells [53–55]. Here, MAP2K7 is linked to endometrial cancer.